



## AML: Fast Track to Transplant

Saturday, November 10, 2018

12:30 p.m. – 1:30 p.m.

### Speakers

John Pagel, MD, PhD, Steve Spellman, MBS

### Session Objectives

At the conclusion of this session, attendees will be able to:

1. Describe the diagnosis of AML and Risk assessment testing
2. List traditional treatment options
3. Evaluate results of SWOG 1203 trial
4. Recall Intervention at diagnosis opportunities

### Conflict of Interest/Financial Disclosure

The planners and speaker(s) have disclosed the following financial relationships and/or conflicts of interest:

John Pagel, MD, PhD	Actinium Pharmaceuticals
Maria Brown	None
Misty Evans	Jazz Pharmaceuticals, Monetary, Speakers Bureau
Steve Spellman, MBS	None